Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Christopher Haqq sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $12.65, for a total value of $75,900.00. Following the transaction, the executive vice president now directly owns 368,080 shares in the company, valued at $4,656,212. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Christopher Haqq also recently made the following trade(s):
- On Monday, April 17th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The shares were sold at an average price of $17.28, for a total value of $103,680.00.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) traded up 3.66% during midday trading on Friday, reaching $12.75. The company’s stock had a trading volume of 863,109 shares. The firm has a 50 day moving average price of $14.56 and a 200-day moving average price of $16.30. The company’s market cap is $371.14 million. Atara Biotherapeutics, Inc. has a 12-month low of $11.80 and a 12-month high of $25.73.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by WKRB News and is owned by of WKRB News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.wkrb13.com/markets/2229036/insider-selling-atara-biotherapeutics-inc-atra-evp-sells-6000-shares-of-stock.html.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Atara Biotherapeutics during the first quarter worth about $132,000. Elkfork Partners LLC bought a new position in shares of Atara Biotherapeutics during the fourth quarter worth about $135,000. DekaBank Deutsche Girozentrale bought a new position in shares of Atara Biotherapeutics during the first quarter worth about $185,000. American International Group Inc. increased its position in shares of Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Atara Biotherapeutics by 37.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 21,797 shares of the biotechnology company’s stock worth $310,000 after buying an additional 5,883 shares in the last quarter. Institutional investors and hedge funds own 82.11% of the company’s stock.
Several brokerages recently weighed in on ATRA. Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Canaccord Genuity reaffirmed a “buy” rating and issued a $47.00 price target on shares of Atara Biotherapeutics in a research note on Friday, April 21st. Finally, Citigroup Inc. set a $10.00 price target on Atara Biotherapeutics and gave the stock a “sell” rating in a research note on Thursday, March 16th. Three investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $24.00.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229036/insider-selling-atara-biotherapeutics-inc-atra-evp-sells-6000-shares-of-stock.html
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.